Engaging Innovation | Friends of Cancer Research

Engaging Innovation

Featured Post

March 14, 2019

Data Driven: How Oncologists Perceive FDA-Approved Drug Labeling Compared to Other Major Prescribing Resources

Physicians rely on a variety of sources of information to provide high-quality care to patients. In oncology, some of the most prominent resources that inform provider decision-making are the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) clinical practice guidelines; drug compendia; electronic point-of-care decision...
More Posts

Recent Posts

No Results With Current Filter Choices

The FDA’s Budget: How Government Funds Safety and Efficacy

The U.S. Food and Drug Administration (FDA) fulfills its mission to protect and advance the public health by overseeing the development and approval of new medical products and ensuring that they are safe and effective for American consumers. When taking into consideration the full range of products the FDA oversees,...

The Future Use of Real-World Evidence

  Significant progress has been made in data collection efforts to support use of real-world evidence (RWE) in regulatory settings; however challenges remain, chiefly with combining, organizing, and analyzing data from various information sources. On July 10th, Friends of Cancer Research (Friends) hosted a meeting to present data from a pilot...

TMB Harmonization Working Group Meeting

On May 10, 2018, Friends of Cancer Research (Friends) convened stakeholders across all health sectors to assess current methods of measuring tumor mutational burden (TMB) and develop a consensus approach to the standardization of this biomarker. This roundtable built on a workshop hosted by Friends in the Fall of 2017,...

Safeguarding the Public Health: Enhancing Information About Prescription Drugs

Friends of Cancer Research Congressional BriefingSafeguarding the Public Health: Enhancing Information About Prescription Drugs Patients and their caregivers need access to high quality information about the prescription drugs they use. While many sources of information exist, none can deliver as strong assurances of reliability and scientific rigor as FDA-approved product labels....

Molecularly Targeted Therapies in Pediatric Cancer

Robust drug development for pediatric cancers is critical to ensuring appropriate access to life-saving drugs and promoting innovation. As such, the FDA Reauthorization Act (FDARA) of 2017 included a provision requiring sponsors to investigate new molecularly targeted cancer drugs and biologics that are determined to be substantially relevant to the...

A Plea to Make Cancer Clinical Trials More Patient Friendly

Jim Omel is a myeloma patient and a cancer research advocate. He spoke at the 2017 Friends of Cancer Research Annual Meeting and was an author of the panel 2 whitepaper, Data Generation to Support Cross-Labeling of Indications for Combination Products. Below are his abridged remarks from the meeting. To...

Biopharma Congress III

November 14, 2017Disruption In BiopharmaThe Ritz-Carlton, Washington D.C.1150 22nd Street, NW On Tuesday, November 14, 2017, Friends of Cancer Research (Friends) and Prevision Policy hosted the third annual BioPharma Congress. This year’s event focused on disruption in biopharma and featured speakers such as former FDA Commissioner Dr. Mark McClellan and former...
Back to Top